• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新冠病毒XBB奥密克戎亚变体是否预示着大流行结束的开始?

Does the COVID-19 XBB Omicron subvariant signal the beginning of the end of the pandemic?

作者信息

Ngiam Jinghao Nicholas, Al-Mubaarak Abdurrahmaan, Maurer-Stroh Sebastian, Tambyah Paul Anantharajah

机构信息

Division of Infectious Diseases, Department of Medicine, National University Health System, Singapore.

Bioinformatics Institute and Infectious Diseases Labs, Agency for Science Technology and Research, Singapore.

出版信息

Singapore Med J. 2024 Dec 1;65(12):658-664. doi: 10.4103/singaporemedj.SMJ-2022-180. Epub 2022 Dec 1.

DOI:10.4103/singaporemedj.SMJ-2022-180
PMID:36648003
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11698282/
Abstract

All pandemic viruses have eventually adapted to human hosts so that they become more transmissible and less virulent. The XBB Omicron subvariant is rapidly becoming the dominant strain of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in Singapore from October 2022 and is one of several variants circulating globally with the potential to dominate autumn/winter waves in different countries. The XBB Omicron subvariant has demonstrated increased transmissibility through an apparent propensity for immune evasion. This is to be expected in the natural evolution of a virus in a population highly vaccinated with a vaccine targeting the spike protein of the original Wuhan strain of the virus. This review explores the important implications of the rising prevalence of the SARS-CoV-2 Omicron subvariant for public health in Singapore and beyond.

摘要

所有大流行病毒最终都适应了人类宿主,从而变得更具传播性且毒性更低。XBB奥密克戎亚变体自2022年10月起迅速成为新加坡严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的主要毒株,是全球正在传播的几种变体之一,有可能在不同国家主导秋冬疫情高峰。XBB奥密克戎亚变体通过明显的免疫逃逸倾向表现出更强的传播性。在一个针对该病毒原始武汉毒株刺突蛋白进行了高度疫苗接种的人群中,病毒的自然进化会出现这种情况。本综述探讨了SARS-CoV-2奥密克戎亚变体流行率上升对新加坡及其他地区公共卫生的重要影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/091c/11698282/35ddfb0589f5/SMJ-65-658-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/091c/11698282/20c30db33036/SMJ-65-658-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/091c/11698282/f1830b064b39/SMJ-65-658-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/091c/11698282/35ddfb0589f5/SMJ-65-658-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/091c/11698282/20c30db33036/SMJ-65-658-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/091c/11698282/f1830b064b39/SMJ-65-658-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/091c/11698282/35ddfb0589f5/SMJ-65-658-g003.jpg

相似文献

1
Does the COVID-19 XBB Omicron subvariant signal the beginning of the end of the pandemic?新冠病毒XBB奥密克戎亚变体是否预示着大流行结束的开始?
Singapore Med J. 2024 Dec 1;65(12):658-664. doi: 10.4103/singaporemedj.SMJ-2022-180. Epub 2022 Dec 1.
2
Comprehensive Analysis of Omicron Subvariants: EG.5 Rise, Vaccination Strategies, and Global Impact.奥密克戎亚型的综合分析:例如,EG.5 崛起、疫苗接种策略和全球影响。
Curr Drug Targets. 2024;25(8):517-525. doi: 10.2174/0113894501296586240430061915.
3
Early 2022 breakthrough infection sera from India target the conserved cryptic class 5 epitope to counteract immune escape by SARS-CoV-2 variants.2022年初来自印度的突破性感染血清靶向保守的隐秘5类表位以对抗SARS-CoV-2变体的免疫逃逸。
J Virol. 2025 Apr 15;99(4):e0005125. doi: 10.1128/jvi.00051-25. Epub 2025 Mar 26.
4
SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.严重急性呼吸综合征冠状病毒2型奥密克戎XBB亚变体在老年人群中表现出增强的融合性和显著的免疫逃逸能力,但对泛冠状病毒融合抑制剂高度敏感。
J Med Virol. 2023 Mar;95(3):e28641. doi: 10.1002/jmv.28641.
5
Evolutionary and Phylogenetic Dynamics of SARS-CoV-2 Variants: A Genetic Comparative Study of Taiyuan and Wuhan Cities of China.SARS-CoV-2 变异株的进化与系统发育动态:中国太原市与武汉市的遗传比较研究。
Viruses. 2024 Jun 3;16(6):907. doi: 10.3390/v16060907.
6
Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.新加坡一项全国性队列研究:SARS-CoV-2 感染和疫苗对有医疗记录的奥密克戎 BA.4、BA.5 和 XBB 再感染相关症状的保护免疫作用。
Lancet Infect Dis. 2023 Jul;23(7):799-805. doi: 10.1016/S1473-3099(23)00060-9. Epub 2023 Mar 13.
7
Immunogenicity and efficacy of XBB.1.5 rS vaccine against the EG.5.1 variant of SARS-CoV-2 in Syrian hamsters.XBB.1.5 rS 疫苗在叙利亚仓鼠中针对 SARS-CoV-2 的 EG.5.1 变异株的免疫原性和疗效。
J Virol. 2024 Oct 22;98(10):e0052824. doi: 10.1128/jvi.00528-24. Epub 2024 Sep 4.
8
Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study.丹麦全国性观察研究:与 SARS-CoV-2 奥密克戎亚变体 BA.2.86 和后代 JN.1 相关的相对疫苗保护、疾病严重程度和症状。
Lancet Infect Dis. 2024 Sep;24(9):964-973. doi: 10.1016/S1473-3099(24)00220-2. Epub 2024 May 15.
9
XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants.XBB.1.5 刺突蛋白 COVID-19 疫苗诱导针对 EG.5.1 和新兴 XBB 变异株的广泛中和及细胞免疫应答。
Sci Rep. 2023 Nov 6;13(1):19176. doi: 10.1038/s41598-023-46025-y.
10
Structural Basis for the Enhanced Infectivity and Immune Evasion of Omicron Subvariants.结构基础:奥密克戎亚变体增强的传染性和免疫逃避能力。
Viruses. 2023 Jun 20;15(6):1398. doi: 10.3390/v15061398.

引用本文的文献

1
Spatiotemporal dynamics and epidemiological impact of SARS-CoV-2 XBB lineage dissemination in Brazil in 2023.2023 年 SARS-CoV-2 XBB 谱系在巴西的传播时空动态及其流行病学影响。
Microbiol Spectr. 2024 Mar 5;12(3):e0383123. doi: 10.1128/spectrum.03831-23. Epub 2024 Feb 5.

本文引用的文献

1
Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution.印迹 SARS-CoV-2 体液免疫诱导奥密克戎 RBD 进化趋同。
Nature. 2023 Feb;614(7948):521-529. doi: 10.1038/s41586-022-05644-7. Epub 2022 Dec 19.
2
The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies.关注的奥密克戎变异株:刺突蛋白的多样化和趋同进化,以及逃避抗刺突单克隆抗体。
Drug Resist Updat. 2022 Dec;65:100882. doi: 10.1016/j.drup.2022.100882. Epub 2022 Oct 3.
3
COVID-19 update: Bivalent Pfizer and Moderna COVID-19 vaccines for booster immunization.
新冠疫情最新消息:用于加强免疫的辉瑞和莫德纳二价新冠疫苗。
Med Lett Drugs Ther. 2022 Oct 3;64(1660):159-160.
4
Serum creatinine to absolute lymphocyte count ratio effectively risk stratifies patients who require intensive care in hospitalized patients with coronavirus disease 2019.血清肌酐与绝对淋巴细胞计数比值能有效对 2019 年冠状病毒病住院患者中需要重症监护的患者进行危险分层。
Medicine (Baltimore). 2022 Sep 23;101(38):e30755. doi: 10.1097/MD.0000000000030755.
5
SARS-CoV-2 Omicron variant emerged under immune selection.SARS-CoV-2 奥密克戎变异株是在免疫选择压力下出现的。
Nat Microbiol. 2022 Nov;7(11):1756-1761. doi: 10.1038/s41564-022-01246-1. Epub 2022 Oct 4.
6
A Bivalent Omicron-Containing Booster Vaccine against Covid-19.二价含奥密克戎成分的新冠病毒加强疫苗。
N Engl J Med. 2022 Oct 6;387(14):1279-1291. doi: 10.1056/NEJMoa2208343. Epub 2022 Sep 16.
7
Proportion of asymptomatic infection and nonsevere disease caused by SARS-CoV-2 Omicron variant: A systematic review and analysis.奥密克戎变异株引起的 SARS-CoV-2 无症状感染和非重症疾病的比例:系统评价和分析。
J Med Virol. 2022 Dec;94(12):5790-5801. doi: 10.1002/jmv.28066. Epub 2022 Aug 24.
8
In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5.治疗性抗体对 SARS-CoV-2 奥密克戎 BA.1、BA.2 和 BA.5 的体外活性。
Sci Rep. 2022 Jul 23;12(1):12609. doi: 10.1038/s41598-022-16964-z.
9
Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission.奥密克戎变异株 BA.1 至 BA.5 的进化:免疫逃逸和传播的影响。
Rev Med Virol. 2022 Sep;32(5):e2381. doi: 10.1002/rmv.2381. Epub 2022 Jul 20.
10
Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.恢复期血清和疫苗血清及单克隆抗体对 SARS-CoV-2 奥密克戎亚变种 BA.1 和 BA.2 的中和作用有限。
EBioMedicine. 2022 Aug;82:104158. doi: 10.1016/j.ebiom.2022.104158. Epub 2022 Jul 11.